Description

▪ Introduction

Stanoxin by Proton Pharma delivers 10 mg of pharmaceutical-grade Stanozolol per oral tablet. Originally developed for the treatment of hereditary angioedema and other catabolic conditions, Stanozolol is studied in laboratory and analytical research settings for its non-aromatizing androgenic profile and support in preserving nitrogen balance. Proton Pharma manufactures this formulation under stringent quality control to ensure consistent purity and dosage accuracy, tailored for professional research environments.

▪ Product Details 

• Active Ingredient: Stanozolol

• Dosage Strength: 10 mg per tablet

• Form: Oral tablets

• Brand: Proton Pharma

• Package Size: 100 tablets

• Intended Use: Laboratory and analytical use

▪ Pharmacokinetics

Stanozolol is orally bioavailable and has a short half-life ranging between 9 to 12 hours. It does not convert to estrogen, making it suitable for research protocols examining androgenic effects without estrogenic interference. The compound is hepatically metabolized and excreted via the urinary tract.

▪ Usage Recommendations

• Typical Dosage (historic medical context): Administered daily under physician supervision for specific clinical applications

• Current Use: For laboratory and analytical research only

• Administration: Oral

▪ Disclaimer

This product is intended strictly for laboratory and analytical use. It is not approved for human consumption or therapeutic use. Not suitable for individuals under 18, pregnant or breastfeeding women, or those with medical conditions. All handling must adhere to local regulations, institutional guidelines, and professional research standards.